82357-48-0

Basic information

• Product Name: C3-NITRO-4-METHYLAMINO-BENZOYLCHLORIDE
• Synonyms: 3-NITRO-4-METHYLAMINO-BENZOYLCHLORIDE;4-Methylamino-3-nitro-benzoic acid chloride;4-Methylamino-3-nitrobenzoyl chloride;Benzoyl chloride, 4-(MethylaMino)-3-nitro-;C3-NITRO-4-METHYLAMINO-BENZOYLCHLORIDE;Benzoyl chloride, 4-(methylamino)-3-nitro- (9CI)
• CAS NO: 82357-48-0
• Molecular Formula: C₈H₇ClN₂O₃
• Molecular Weight: 214.60578
• EINECS: 1533716-785-6
• Product Categories: ACIDHALIDE
• Mol File: 82357-48-0.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 353.3°C at 760 mmHg
• Flash Point: 167.5°C
• Appearance: /
• Density: 1.458±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 3.62E-05mmHg at 25°C
• Refractive Index: 1.634
• CAS DataBase Reference: C3-NITRO-4-METHYLAMINO-BENZOYLCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: C3-NITRO-4-METHYLAMINO-BENZOYLCHLORIDE(82357-48-0)
• EPA Substance Registry System: C3-NITRO-4-METHYLAMINO-BENZOYLCHLORIDE(82357-48-0)

Safety Data

• Hazardous Substances Data: 82357-48-0(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C8H7ClN2O3/c1-10-6-3-2-5(8(9)12)4-7(6)11(13)14/h2-4,10H,1H3

Upstream product

• 1187067-71-5 4-(methylamine)-3-nitrobenzoic acid hydrochloride 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 41263-74-5 4-(methylamino)-3-nitrobenzoic acid 

Downstream Products

• 315681-66-4 4-methylamino-3-nitro-benzoic acid 2-trimethylsilanyl-ethyl ester 
• 429658-94-6 [(4-methylamino-3-nitro-benzoyl)phenyl-amino]acetic acid ethyl ester 
• 429659-01-8 ethyl 3-{[{1-(methylamino)-2-nitrophen-4-yl}carbonyl](pyridyn-2-yl)amino}propanoate 
• 211915-71-8 4-methylamino-3-nitro-benzoic acid-N-phenyl-N-(2-ethoxycarbonylethyl)amide 
• 429659-00-7 4-[(4-methylamino-3-nitro-benzoyl)-phenyl-amino]-butyric acid ethyl ester 
• 41263-66-5 4-Methylamino-3-nitro-benzamid 
• 39033-67-5 3-amino-4-(methylamino)benzamide 
• 212322-56-0 ethyl 3-{[{2-amino-1-(methylamino)phen-4-yl}carbonyl](pyridyn-2-yl)amino}propanoate 
• 211915-72-9 3-Amino-4-methylamino-benzoic acid-N-phenyl-N-(2-ethoxy-carbonylethyl)-amide 
• 211916-27-7 4-[(3-amino-4-methylamino-benzoyl)-phenyl-amino]-butyric acid ethyl ester 
• 211916-29-9 1-methyl-2-[(4-cyanophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide 
• 211916-28-8 1-methyl-2-[2-(4-cyanophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide 
• 211916-30-2 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide 
• 211915-73-0 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide 

Relevant articles and documents

Novel potent benzimidazole-based microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C4 synthase

Microsomal prostaglandin E2 synthase-1 (mPGES-1) is recognized as a promising therapeutic target for next-generation anti-inflammatory drugs to treat inflammatory diseases. In this study, we report the identification of new, potent and selectiv

Computer-aid drug design, synthesis, and anticoagulant activity evaluation of novel dabigatran derivatives as thrombin inhibitors

In this study, computer-aided drug design techniques were adopted to explore the structural and chemical features for dabigatran and design novel derivatives. The built 3D-QSAR models demonstrated significant statistical quality and excellent predictive ability by internal and external validation. Based on QSAR information, 11 novel dabigatran derivatives (12a–12k) were designed and predicted, then ADME prediction and molecular docking were performed. Furthermore, all designed compounds were synthesized and characterized by 1H NMR, 13C NMR and HR-MS. Finally, they were evaluated for anticoagulant activity in vitro. The activity results showed that the 10 obtained compounds exhibited comparable activity to the reference dabigatran (IC50 = 9.99 ± 1.48 nM), except for compound 12i. Further analysis on molecular docking was performed on three compounds (12a, 12c and 12g) with better activity (IC50 = 11.19 ± 1.70 nM, IC50 = 10.94 ± 1.85 nM and IC50 = 11.19 ± 1.70 nM). MD simulations (10 ns) were carried out, and their binding free energies were calculated, which showed strong hydrogen bond and pi–pi stacking interactions with key residues Gly219, Asp189 and Trp60D. The 10 novel dabigatran derivatives obtained can be further studied as anticoagulant candidate compounds.

Synthesis, Crystal Structure, and Anti-Gastric Cancer Activity of Ethyl 3-(3-Amino-4-(Methylamino)-N-(Pyridin-2-Yl) Benzamido)Propanoate

A new heterocyclic compound ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate (1), designed using 4-(methylamino)-3-nitrobenzoic acid (2) as a starting material is successfully obtained via a multiple synthesis route and finally characterized by IR, 1H NMR, and single crystal X-ray crystallography. In addition, the in vitro anti-cancer activity of newly synthesized complex 1 is emulated against three human gastric cancer cell lines SGC-790, MKN-4, and MKN45.